The present invention provides a compound exhibiting
coronavirus 3CL
protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Provided is a compound represented by Formula (I): wherein Ring A is a ring represented by: wherein X is a
single bond or the like, R2 is substituted or unsubstituted aromatic carbocyclyl or the like, R3c is substituted or unsubstituted aromatic carbocyclyl or the like, R3 is substituted or unsubstituted aromatic carbocyclyl or the like, R3a is a
hydrogen atom or the like, R3b is a
hydrogen atom, R8a is substituted or unsubstituted aromatic carbocyclyl or the like, and R8b is a
hydrogen atom or the like, R1 is a substituted or unsubstituted aromatic heterocyclyl, m is 0 or the like, R5a is each independently a
hydrogen atom or the like, R5b is each independently a
hydrogen atom or the like, R6 is cyano or the like, and R7a and R7b are each independently a
hydrogen atom or the like, or a pharmaceutically acceptable salt of the compound.